[Severe sicca syndrome associated with primary biliary cirrhosis. Value of an immunosuppressive treatment]. 1995

H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine
D012859 Sjogren's Syndrome Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis. Sicca Syndrome,Sjogren Syndrome,Sjogrens Syndrome,Syndrome, Sicca,Syndrome, Sjogren's

Related Publications

H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
July 1994, Scandinavian journal of gastroenterology,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
May 1994, Cutis,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
January 2007, Modern rheumatology,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
April 2003, Nippon Ganka Gakkai zasshi,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
November 1973, Proceedings of the Royal Society of Medicine,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
January 1997, Dysphagia,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
January 2015, Journal of clinical gastroenterology,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
October 1997, Israel journal of medical sciences,
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
July 1998, Internal medicine (Tokyo, Japan),
H Rifflet, and P Calés, and F Oberti, and I Fouchard, and M C Rousselet, and J Cottereau, and Y Deugnier, and J Dubin, and C Masson
July 2010, La Revue de medecine interne,
Copied contents to your clipboard!